BR112023020600A2 - Método para tratar ou prevenir uma infecção, e, uso de um composto - Google Patents

Método para tratar ou prevenir uma infecção, e, uso de um composto

Info

Publication number
BR112023020600A2
BR112023020600A2 BR112023020600A BR112023020600A BR112023020600A2 BR 112023020600 A2 BR112023020600 A2 BR 112023020600A2 BR 112023020600 A BR112023020600 A BR 112023020600A BR 112023020600 A BR112023020600 A BR 112023020600A BR 112023020600 A2 BR112023020600 A2 BR 112023020600A2
Authority
BR
Brazil
Prior art keywords
infection
treating
preventing
sars
compound
Prior art date
Application number
BR112023020600A
Other languages
English (en)
Inventor
Franck Amblard
Junxing Shi
Keivan Zandi
Longhu Zhou
Mahesh Kasthuri
Nicolas Biteau
Raymond Schinazi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BR112023020600A2 publication Critical patent/BR112023020600A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método para tratar ou prevenir uma infecção, e, uso de um composto. compostos, composições e métodos para prevenir, tratar ou curar uma infecção por coronavírus em sujeitos humanos ou outros hospedeiros animais. em uma modalidade, os compostos podem ser usados para tratar uma infecção com um vírus da síndrome respiratória aguda grave, tal como coronavírus humano 229e, sars, mers, sars-cov-1, oc43 e sars-cov-2. em outra modalidade, os métodos são usados para tratar um paciente infectado com um flavivírus, picornavus, togavirus ou bunyavirus.
BR112023020600A 2021-04-09 2022-04-11 Método para tratar ou prevenir uma infecção, e, uso de um composto BR112023020600A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163173354P 2021-04-09 2021-04-09
US202163175673P 2021-04-16 2021-04-16
US202163210246P 2021-06-14 2021-06-14
US202163288163P 2021-12-10 2021-12-10
US202263298836P 2022-01-12 2022-01-12
PCT/US2022/024286 WO2022217153A2 (en) 2021-04-09 2022-04-11 Nucleosides and nucleotides analogs as antiviral agents

Publications (1)

Publication Number Publication Date
BR112023020600A2 true BR112023020600A2 (pt) 2023-12-12

Family

ID=83546595

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112023020798A BR112023020798A2 (pt) 2021-04-09 2022-04-11 Método para tratar ou prevenir uma infecção, e, uso de um composto
BR112023020600A BR112023020600A2 (pt) 2021-04-09 2022-04-11 Método para tratar ou prevenir uma infecção, e, uso de um composto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112023020798A BR112023020798A2 (pt) 2021-04-09 2022-04-11 Método para tratar ou prevenir uma infecção, e, uso de um composto

Country Status (8)

Country Link
EP (3) EP4319763A2 (pt)
JP (2) JP2024514825A (pt)
KR (2) KR20240006536A (pt)
AU (2) AU2022254108A1 (pt)
BR (2) BR112023020798A2 (pt)
CA (3) CA3214918A1 (pt)
IL (2) IL307478A (pt)
WO (3) WO2022217154A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
AU2021251689A1 (en) 2020-04-06 2022-11-17 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
WO2021262826A2 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
TW202228722A (zh) 2020-08-27 2022-08-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
CN116284135A (zh) * 2023-05-04 2023-06-23 南京颐媛生物医学研究院有限公司 抗冠状病毒核苷类化合物的制备方法及其应用
CN116332996A (zh) * 2023-05-04 2023-06-27 南京颐媛生物医学研究院有限公司 抗冠状病毒化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
US5128458A (en) * 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
WO2005027962A1 (en) * 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
CA2596424C (en) * 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
US20110269814A1 (en) * 2008-03-26 2011-11-03 Alnylam Pharamaceuticals, Inc. 2'-f modified rna interference agents
BR112013026219A2 (pt) * 2011-04-13 2016-07-26 Gilead Sciences Inc análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral
US10005779B2 (en) * 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV

Also Published As

Publication number Publication date
EP4319762A2 (en) 2024-02-14
WO2022217155A3 (en) 2022-11-17
WO2022217154A3 (en) 2022-11-17
EP4319764A2 (en) 2024-02-14
KR20230170015A (ko) 2023-12-18
WO2022217155A2 (en) 2022-10-13
AU2022253068A1 (en) 2023-10-26
IL307486A (en) 2023-12-01
CA3214726A1 (en) 2022-10-13
WO2022217153A2 (en) 2022-10-13
AU2022254108A1 (en) 2023-10-26
WO2022217154A2 (en) 2022-10-13
IL307478A (en) 2023-12-01
JP2024513571A (ja) 2024-03-26
KR20240006536A (ko) 2024-01-15
BR112023020798A2 (pt) 2023-12-19
CA3214904A1 (en) 2022-10-13
EP4319763A2 (en) 2024-02-14
JP2024514825A (ja) 2024-04-03
CA3214918A1 (en) 2022-10-13
WO2022217153A3 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
BR112023020600A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
BR112023000323A2 (pt) Vacina combinada contra sars-cov-2 e influenza
BR112018016755A2 (pt) vacina contra o vírus da zica
BR112018075960A2 (pt) moléculas de ácido nucleico para a redução de mrna de papd5 ou papd7 para o tratamento de infecção pela hepatite b
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
BRPI0509467A (pt) compostos macrocìclicos como inibidores de replicação viral
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
BR112022016893A8 (pt) Vacina contra a infecção do vírus da peste suína africana
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
DE602005008264D1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
BR112022019558A2 (pt) Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero
BR112022023135A2 (pt) Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas
BR112023000650A2 (pt) Vírus vaccinia recombinante
BR112022019876A2 (pt) Composições virucidas, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso das composições virucidas
BR112019012057A2 (pt) agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv)